Colorectal Cancer Panel

 
Test code: GDB274

Related gene(s): APC, ATM, AXIN2, BMPR1A, CDH1, CHEK2, CTNNA1, EPCAM, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SCG5 (GREM1), SMAD4, STK11, TP53

Test description:

The Colorectal Cancer Panel includes genes associated with increased risk for colorectal cancer. This includes genes associated with lynch syndrome, familial adenomatous polyposis (FAP), attenuated familial adenomatous polyposis (AFAP), and MUTYH-associated polyposis. This panel can provide information that may help healthcare providers and patients make more informed decisions regarding treatment, prevention, and surveillance.

Conditions:

    • Colorectal Cancer
    • Familial Adenomatou Polyposis (FAP)
    • Attenuated Familial Adenomatous Polyposis (AFAP)

     
    Clinical utility:

    • Colorectal or endometrial cancer diagnosed under 50 years of age
    • Multiple colon polyps (especially ≥ 20 adenomas) at any age
    • Tumor testing which indicates an increased risk for a hereditary cancer syndrome known as Lynch syndrome (e.g. microsatellite instability and/or lack of immunohistochemistry staining for a mismatch repair protein)
    • Multiple cancers in one person either of the same origin (such as two separate colorectal cancers) or of different origin (such as colon and endometrial cancer in the same individual)
    • Multiple relatives diagnosed with the same or related cancers (such as colon, endometrial, ovarian, urinary tract, gastric) on the same side of the family and spanning multiple generations

     
    Lab method:

    • Deletion/duplication analysis
    • Next-Gen sequencing

    Specimen Requirements

    • Preferred: 2-5 mL Blood – Lavender Top Tube
    • Alternative: Buccal Swabs, Fibroblasts (separate charge for cell culture may apply)

    Ordering Information

    • CPT code(s):* 81435×1, 81436×1
    • Turnaround Time:** 2 weeks


    *The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
    **Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.


    Resources

    Hereditary Cancer Requisition
    Hereditary Cancer Re-requisition
    GeneDx Test Information Sheet (TIS)